# SUBLIVAC® Birch PROBE Study

> **NCT00932607** · PHASE2 · COMPLETED · sponsor: **HAL Allergy** · enrollment: 74 (actual)

## Conditions studied

- Seasonal Rhinitis and/or Rhinoconjunctivitis
- Birch Pollen Allergy

## Interventions

- **DRUG:** sublingual immunotherapy

## Key facts

- **NCT ID:** NCT00932607
- **Lead sponsor:** HAL Allergy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-02
- **Final completion:** —
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2012-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00932607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00932607, "SUBLIVAC® Birch PROBE Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00932607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*